- Recommended for adoption at Step 8, the Draft
Maximum Residue Limits for levamisole (liver/cattle, sheep, pigs) and for
triclabendazole (muscle/cattle; liver and kidney/cattle; and muscle, liver and
kidney/sheep) (paras. 29-30; Appendix II);- Recommended for adoption at Step 5 by the Executive
Committee, the Proposed Draft Maximum Residue Limits for carazolol, ceftiofur
sodium, doramectin, moxidectin and spiramycin (paras. 34, 36, 41-42 & 44;
Appendix IV);
- Agreed on a Priority List of Veterinary Drugs Requiring
Evaluation or Reevaluation (paras. 57-59; Appendix VI);
- Agreed to amend the previously recommended methods of
analysis for the existing Codex Maximum Residue Limits for Veterinary Drugs
(paras. 48; Appendix VII); ad Proposed to elaborate guidelines on residues at
injection sites (paras. 26, 66).
- Agreed that at this stage the Committee did not
wish to provide further input on the Programme Area of biotechnology to the
Commission; however, expressed interest in reviewing future documents on this
issue (para. 6);- Decided to review the Codex Guidelines for the Establishment
of a Regulatory Programmes for Control of Veterinary Drug Residues in Foods to
assess whether these address appropriately the issue of control of veterinary
drug residues in raw milk and milk products (para. 9);
- Supported the incorporation of a science-based approach to
risk analysis into its work and agreed that a discussion paper should be for
consideration at its 10th Session (para. 14);
- Strongly supported the creation of an International
Cooperation on the Harmonization of Technical Requirements for Registration of
Veterinary Medicinal Products (para. 22);
- Requested a paper containing guidance for determining the
classes or formulations of drugs that would cause problems relating injection
site residues and proposed draft guidelines for dealing with injection site
residues (para. 26);
- Decided that that if no method of analysis acceptable to the
Committee was recommended to monitor an MRL, the MRL should not be advanced
beyond Step 7 and reaffirmed that temporary MRLs should be retained at Step 4
(paras. 27 & 32);
- Retained at Step 7 the Draft Maximum Residue Limits for
levamisole (muscle, kidney, fat/cattle, cheep, pigs, poultry; and
liver/poultry); for triclabendazole (fat/cattle, sheep); and for diminazene
(all) as they were not supported by methods of analysis (paras. 28 & 30-31;
Appendix III);
- Retained at Step 4 all temporary MRLs for apaperone,
carazolol, chlortetracycline/ tetracycline, dexamethasone, diclazuril,
dihydrostreptomycin/streptomycin, febantel/ fenbendazole/oxfendazole,
gentamicin, moxidectin, neomycin, oxytetracycline, spectinomycin and spiramycin
(paras. 34, 36, 39, 42 & 45; Appendix V);
- Agreed to withdraw the MRL for levamisole in milk (para.
40);
- Made a series of recommendations on methods of analysis
(para. 48):
- Supported the proposal that greater emphasis should be given
to the availability of analytical methods for compounds to be considered for
JECFA evaluation (para. 49);
- Agreed that MRLs should be developed independently of
validated methods (para. 54);
- Requested a paper for consideration at its next Session on
the criteria for validated analytical methods (para. 54); and
- Agreed that a progress report on the Compendium
of Veterinary Drugs would be presented at its next Session (para.
63).
